| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Luzindole targets melatonin receptors, specifically the MT₂ (Mel1b) and MT₁ (Mel1a) receptors. It acts as a selective antagonist with preferential activity toward MT₂ over MT₁. The compound has Ki values of 10.2 nM for human MT2 and 158 nM for human MT1. By blocking melatonin receptors, luzindole inhibits melatonin-mediated signaling.
|
|---|---|
| ln Vitro |
MBP-reactive LV-4 T cell lines' antigen-specific proliferation is inhibited by luteindole (N-0774) (5–10 μg/ml) [1].
In vitro, luzindole acts as a selective melatonin receptor antagonist with Ki values of 10.2 nM for human MT2 and 158 nM for human MT1. It significantly antagonizes melatonin-mediated antinociception. The compound is used as a tool to study melatonin receptor function and signaling. |
| ln Vivo |
Experimental autoimmune encephalomyelitis is inhibited by luzindole (N-0774) (30 mg/kg; i.p.; days 0-5) [2]. In a dose-dependent manner, luzindole (N-0774) (30 mg/kg ip) shortens immobility time; the impact is greater at midnight (60% decrease) than it is at midday (39% reduction). Luzindole's effects are time-dependent, peaking after 60 minutes. The anti-immobility effects of luzidole (10 mg/kg ip) are countered by the administration of melatonin (30 mg/kg ip). Luzindole (30 mg/kg ip) does not change albino ND/4 mice's or C57BL/6J mice's non-melatonin-producing immobility time at midday or midnight [3].
In vivo, luzindole has been studied for its potential applications in sleep disorders and circadian rhythm regulation due to its ability to modulate melatonin signaling. It significantly antagonizes melatonin-mediated antinociception, suggesting that melatonin receptors play a role in pain signaling. Specific efficacy data and dosing regimens are limited. |
| Enzyme Assay |
Non-cellular receptor binding assays for luzindole involve radioligand displacement using membrane preparations expressing human MT1 or MT2 melatonin receptors. Membranes are incubated with a radiolabeled melatonin ligand and varying concentrations of luzindole. Bound radioactivity is measured by filtration. Ki values are calculated from competition binding curves.
|
| Cell Assay |
In vitro cellular experiments involve cells expressing MT1 or MT2 melatonin receptors. Cells are treated with luzindole in the presence of melatonin. Receptor activation is measured by downstream signaling such as cAMP accumulation. Antagonist potency is determined by measuring the rightward shift of the melatonin dose-response curve.
|
| Animal Protocol |
Animal/Disease Models: 23 to 12 weeks old (SJL , under minimal lighting conditions)
Experimental Results: Effective prevention of experimental autoimmune encephalomyelitis. In vivo animal studies involve administration of luzindole to rodents to assess its effects on melatonin-mediated behaviors. The compound's effects on circadian rhythms, sleep, and pain responses are evaluated. Specific protocols are described in the primary literature. |
| ADME/Pharmacokinetics |
Luzindole has a molecular weight of 292.38 g/mol and a molecular formula of C₁₉H₂₀N₂O. It is soluble in DMSO and ethanol (up to 100 mM). The compound is a synthetic indole derivative.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for luzindole is limited. As a melatonin receptor antagonist, it is expected to have on-target effects related to melatonin signaling modulation. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References |
|
| Additional Infomation |
Luzindole belongs to the indole class of compounds, with a structure similar to tryptophan, except that one amino hydrogen atom is replaced by an acetyl group, and the hydrogen at position 2 is replaced by a benzyl group. It is a melatonin receptor antagonist. Luzindole belongs to both the acetamide and indole classes. Functionally, it is similar to tryptophan.
Luzindole (N-0774) is a selective melatonin receptor antagonist with Ki values of 10.2 nM for human MT2 and 158 nM for human MT1. It is a synthetic indole derivative used as a research tool to study melatonin receptor-mediated signaling. This product is for research purposes only and is not for human therapeutic use. |
| Molecular Formula |
C19H20N2O
|
|---|---|
| Molecular Weight |
292.3749
|
| Exact Mass |
292.157
|
| Elemental Analysis |
C, 78.05; H, 6.90; N, 9.58; O, 5.47
|
| CAS # |
117946-91-5
|
| Related CAS # |
Luzindole HCl;117946-91-5;
|
| PubChem CID |
122162
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
559.6±38.0 °C at 760 mmHg
|
| Melting Point |
44-46°C
|
| Flash Point |
292.2±26.8 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
3.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
364
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C([H])([H])[H])N([H])C([H])([H])C([H])([H])C1C2=C([H])C([H])=C([H])C([H])=C2N([H])C=1C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
WVVXBPKOIZGVNS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)
|
| Chemical Name |
N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide
|
| Synonyms |
Luzindole, N-0774, N0774, N 0774, N-acetyl-2-benzyltryptamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~342.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4203 mL | 17.1016 mL | 34.2032 mL | |
| 5 mM | 0.6841 mL | 3.4203 mL | 6.8406 mL | |
| 10 mM | 0.3420 mL | 1.7102 mL | 3.4203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
